In this cohort study of patients with advanced solid tumors treated with ICIs in diverse clinics, TMB-H cancers were significantly associated with improved clinical outcomes compared with TMB-L cancers....Our results were generally consistent with our pancancer cohort, with the 1-year survival probability of TMB-H patients being higher than that of TMB-L patients with NSCLC, bladder, melanoma, and CRC (Figure 3).

...however PDL1 expression on greater than 10% of tumor infiltrating immune cells was more closely linked, as this was seen in 50% of patients with complete response compared to 27% with progressive disease (p = 0.06) (Table 1). In addition, certain somatic alterations were associated with complete response while others were associated with progressive disease (Figure 1). As previously described, patients with complete response were more likely to have high TMB than those with progressive disease (p < 0.0001)...

Histologies that were TMB-high included melanoma (N = 6), bladder cancer (N = 2), cutaneous squamous cell carcinoma (N =2), glioblastoma (N = 1), breast cancer (N = 1), basal cell carcinoma (N = 1), esophageal carcinoma (N = 1), and prostate cancer (N = 1)...All patients were treated with either PD-1/L1 or CTLA4 checkpoint blockade (some received a combination of these agents)...The median PFS for TMB-high tumors compared to TMB-Low to -Intermediate tumors was 26.8 months vs. 4.3 months. (P = 0.0173, HR 0.42 [95% CI 0.22–0.77])...